Exudative (Neovascular) age-related macular degeneration

Age-Related Macular Degeneration, Second Edition

Volumn , Issue , 2007, Pages 125-158

  Lim, Jennifer I ^a   Tsong, Jerry W ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863679914     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (165)

1. Pagenstecher H, Genth CP. Atlas Der Patholischen Antomie Des Augapfels. Wiesbaden: CW Kreiden, 1875.
2. Oeller J. Atlas Seltener Ophthalmoscopischer Bufunde. Wiesbaden: Bergmann JF, 1905.
3. Junius P, Kuhnt H. Die Scheibenformige Entartung Der Netzhautmitte (Degeneratio Maculae Luteae Disciformis). Berlin: Karger, 1926.
4. Holloway TB, Verhoeff FH. Disk-like degeneration of the macula. Trans Am Ophthalmol Soc 1928; 26:206.
5. Verhoeff FH, Grossman HP. Pathogenesis of disciform degeneration of the macula. Arch Ophthalmol 1937; 35:262-94.
6. Ashton N, Sorsby A. Fundus dystrophy with unusual features: a histological study. Br J Ophthalmol 1951; 35:751.
7. Gass JDM. Pathogenesis of disciform detachment of the neuroepithelium. III. Senile disciform macular degeneration. Am J Ophthalmol 1967; 63:617.
8. Gass JDM. Pathogenesis of disciform detachment of the neuroepithelium. IV. Fluorescein angiographic study of senile disciform macular degeneration. Am J Ophthalmol 1967; 63:645.
9. Blair CJ, Aaberg TM. Massive subretinal exudation associated with senile macular degeneration. Am J Ophthalmol 1971; 71:639-48.
10. Small ML, Green WR, Alpar JJ, Drewry RE. Senile macular degeneration: a clinicopathologic correlation of two cases with neovascularization beneath the retinal pigment epithelium. Arch Ophthalmol 1976; 94:601-7.
11. Green WR, Key SN, III. Senile macular degeneration: a histopathologic study. Trans Am Ophthalmol Soc 1977; 75:180-254.
12. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102:1640-2.
13. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980; 24:335-610.
14. Hyman LG, Lilienfeld AM, Ferris FL, III, Fine SL. Senile macular degeneration: a case-control study. Am J Epidemiol 1983; 118:213-27.
15. Friedman DS, O’Colmain BJ, Munoz B, et al. Prevelance of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122:564-72.
16. Smiddy WE, Fine SL. Prognosis of patients with bilateral macular drusen. Ophthalmology 1984; 91:271-7.
17. Gregor Z, Joffe L. Senile macular changes in the black African. Br J Ophthalmol 1978; 62:547-50.
18. Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM. Racial differences in the prevalence of agerelated macular degeneration. Ophthalmology 1999; 106:1049-55.
19. Leske MC, Wu SY, Hennis A, et al. Nine-year incidence of age-related macular degeneration in the Barbados Eye Studies. Ophthalmology 2006; 113:29-35.
20. Klein R, Rowland ML, Harris MI. Racial/ethnic differences in age-related maculopathy: third National Health and Nutrition Examination Survey. Ophthalmology 1995; 102:371-81.
21. Varma R, Fraser-Bell S, Tan S, Klein R, Azen SP, Los Angeles Latino Eye Study Group. Prevalence of agerelated macular degeneration in Latinos; the Los Angeles Latino Eye Study. Ophthalmology 2004; 111:1288-97.
22. Munoz B, Klein R, Rodriguez J, Snyder R, West SK. Prevalence of age-related macular degeneration in a population-based sample of Hispanic people in Arizona: Proyecto VER. Arch Ophthalmol 2005; 123:1575-80.
23. Klein R, Klein BEK, Knudson MD, et al. Prevalence of agerelated macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology 2006; 113:373-80.
24. Smith W, Mitchell P. Family history and age-related maculopathy: the Blue Mountain Eye Study. Aust NZ J Ophthalmol 1998; 26:203-6.
25. Klaver CCW, Wolfs RCW, Assink JJM, Duijn CM, Hofman A, deJong PT. Genetic risk of age-related maculopathy: population-based familial aggregation study. Arch Ophthalmol 1998; 116:1646-51.
26. Klein R, Klein BEK, Jensen SC, Mares-Perlman JA, Cruickshanks KJ, Palta M. Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. Ophthalmology 1999; 106:1056-65.
27. Klein R, Klein BEK, Linton KLP, Demets DL. The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking. Am J Epidemiol 1993; 137:190-200.
28. Smith W, Mitchell P, Leeder SR. Smoking and age-related maculopathy: the Blue Mountain Eye Study. Arch Ophthalmol 1996; 114:1518-23.
29. Delacourt C, Diaz JL, Ponton-Sanchez A, Papoz L. Smoking and age-related macular degeneration. The Pola Study. Pathologies oculaires liees a l’age. Arch Ophthalmol 1998; 116:1031-5.
30. Khan JC, Thurlby DA, Shahid H, et al. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 2006; 90:75-80.
31. Espinosa-Heidmann DG, Suner IJ, Catanuto P, Hernandez EP, Marin-Castano ME, Cousins SW. Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental animal model of dry AMD. Invest Ophthalmol Vis Sci 2006; 47:729-37.
32. Taylor HR, West SK, Munoz B, Rosenthal FS, Bressler SB, Bressler NM. The long-term effects of visible light on the eye. Arch Ophthalmol 1992; 110:99-104.
33. Cruickshanks KJ, Klein R, Klein BEK. Sunlight and agerelated macular degeneration: the Beaver Dam Eye Study. Arch Ophthalmol 1993; 111:514-8.
34. The Eye Disease Case-Control Study Group (EDCCS). Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol 1992; 110:1701-8.
35. Darzins P, Mitchell P, Heller RF. Sun exposure and agerelated macular degeneration: an Australian case-control study. Ophthalmology 1997; 104:770-6.
36. Klein R, Klein BEK, Jensen SC, Cruickshanks KJ. The relationship of ocular factors to the incidence and progression of age-related maculopathy. Arch Ophthalmol 1998; 116(4):506-13.
37. Pollack A, Marcovich A, Bukelman A, Oliver M. Agerelated macular degeneration after extracapsular cataract extraction with intraocular lens implantation. Ophthalmology 1996; 103:1546-54.
38. Pollack A, Marcovich A, Bukelman A, Zalish M, Oliver M. Development of exudative age-related macular degeneration after cataract surgery. Eye 1997; 11:523-30.
39. Lanchoney DM, Maguire MG, Fine SL. A model of the incidence and consequences of choroidal neovascularization secondary to age-related macular degeneration: comparative effects of current treatment and potential prophylaxis on visual outcomes in high-risk patients. Arch Ophthalmol 1998; 116:1045-52.
40. Holz FG, Wolfensberger TJ, Piguet B, et al. Bilateral macular drusen in age-related macular degeneration: prognosis and risk factors. Ophthalmology 1994; 101:1522-8.
41. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 1997; 115:741-7.
42. Ferris FL, Davis MD, Clemons TE, et al. A simplified severity scale for AMD: AREDS Report No. 18. Arch Ophthalmol 2005; 123:1570-4.
43. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of highdose supplementation with vitamins C and E, betacarotene, and zinc for age-related macular degeneration and vision loss. AREDS Report No. 8. Arch Ophthalmol 2001; 119:1417-36.
44. Christen WG, Gaziano JM, Hennekens CH. Design of Physicians’ Health Study II—a randomized trial of betacarotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol 2000; 10:125-34.
45. Moeller SM, Parekh N, Tinker L, et al. Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the carotenoids in age-related eye disease study (CAREDS). Ancillary study of the women’s health initiative. Arch Ophthalmol 2006; 124:1151-62.
46. Grossniklaus HE, Miskala PH, Green WR, et al. Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: submacular surgery trials Report No. 7. Arch Ophthalmol 2005; 123:914-21.
47. Grossniklaus HE, Wilson DJ, Bressler SB, et al. Clinicopathologic studies of eyes that were obtained postmortem from four patients who were enrolled in the submacular surgery trials: Report No. 16. Am J Ophthalmol 2006; 141:93-104.
48. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308:385-9.
49. Edwards AO, Ritter R, III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308:421-4.
50. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308:419-21.
51. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs M, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci 2005; 102:7227-32.
52. Mousa SA, Lorelli W, Campochiaro PA. Extracellular matrix-integrin binding modulates secretion of angiogenic growth factors by retinal pigmented epithelial cells. J Cell Biochem 1999; 74:135-43.
53. Bressler NM, Bressler SB, Gragoudas ES. Clinical characteristics of choroidal neovascular membranes. Arch Ophthalmol 1987; 105:209-13.
54. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988; 32:375-413.
55. Moisseiev J, Bressler NM. Asymptomatic neovascular membranes in the second eye of patients with visual loss from age-related macular degeneration. Invest Ophthalmol Vis Sci 1990; 31:462.
56. Alster Y, Bressler NM, Bressler SB, et al. Preferential hyperacuity perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology 2005; 112:1758-65.
57. Goldstein M, Loewenstein A, Barak A, et al. Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age-related macular degeneration. Retina 2005; 25:296-303.
58. Loewenstein A, Malach R, Goldstein M, et al. Replacing the Amsler grid: a new method for monitoring patients with age-related macular degeneration. Ophthalmology 2003; 110:966-70.
59. Valencia M, Green RL, Lopez PF. Echographic findings in hemorrhagic disciform lesions. Ophthalmology 1994; 101:1379-83.
60. Fine AM, Elman MJ, Ebert JE, Prestia PA, Starr JS, Fine SL. Earliest symptoms caused by neovascular membranes in the macula. Arch Ophthalmol 1986; 104:513-4.
61. Nazemi PP, Fink W, Lim JI, Sadun AA. Electronic Amsler grid scotomas of age-related macular degeneration detected and characterized by means of a novel threedimensional computer-automated visual field test. Retina 2005; 25:446-53.
62. Srinivasan VJ, Wojtkowski M, Witkin AJ, et al. Highdefinition and 3-dimensional imaging of macular pathologies with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology 2006; 113:2054-65.
63. Shakoor A, Shahidi M, Blair NP, Gieser JL, Zelkha R. Macular thickness mapping in AMD. Retina 2006; 26:44-8.
64. Lim JI, Aaberg TM, Sr., Capone A, Jr., Sternberg P, Jr. Indocyanine green angiography-guided photocoagulation of choroidal neovascularization associated with retinal pigment epithelial detachment. Am J Ophthalmol 1997; 123:524-32.
65. Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Hope-Ross M, Orlock DR. Digital indocyanine green videoangiography of occult choroidal neovascularization. Ophthalmology 1994; 101:1727-37.
66. Slakter JS, Yannuzzi LA, Sorenson JA, Guyer DR, Ho AC, Orlock D. A pilot study of indocyanine green videoangiography-guided laser photocoagulation of occult choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol 1994; 112:465-72.
67. Elman MJ, Fine SL, Murphy RP, Patz A, Auer C. The natural history of serous retinal pigment epithelium detachment in patients with age-related macular degeneration. Ophthalmology 1986; 93:224-30.
68. Poliner LA, Olk RJ, Burgess D, Gordon ME. Natural history of retinal pigment epithelial detachments in agerelated macular degeneration. Ophthalmology 1986; 93:543-51.
69. Bird AC, Marshall J. Retinal pigment epithelial detachments in the elderly. Trans Ophthalmol Soc UK 1986; 105:674-82.
70. Casswell AG, Kohen D, Bird AC. Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol 1985; 69:397-403.
71. Dhalla MS, Blinder KJ, Tewari A, Hariprasad SM, Apte RS. Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol 2006; 141(4):752-4.
72. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 1991; 109: 1242-57.
73. Lim JI, Sternberg P, Jr., Capone A, Jr., Aaberg TM, Sr., Gilman JP. Selective use of indocyanine green angiography for occult choroidal neovascularization. Am J Ophthalmol 1995; 120:75-82.
74. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006; 113:633-42.
75. Green WR, Enger C. Age-related macular degeneration: histopathologic studies. The 1992 Lorenz E Zimmerman lecture. Ophthalmology 1993; 100:1519-35.
76. Shiraga F, Ojima Y, Matsuo T, Takasu I, Matsui N. Feeder vessel photocoagulation of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 1998; 105:662-9.
77. Staurenghi G, Orzalesi N, La Capria A, Aschero M. Laser treatment of feeder vessels in subfoveal choroidal neovascular membranes. A revisitation using dynamic indocyanine green angiography. Ophthalmology 1998; 2297-305.
78. Flower RW. Optimizing treatment of choroidal neovascularization feeder vessels associated with age-related macular degeneration. Am J Ophthalmol 2002; 134:228-39.
79. Ryan SJ. Subretinal neovascularization: natural history of an experimental model. Arch Ophthalmol 1982; 100:1804-9.
80. Miller H, Miller B, Ryan SJ. The role of the retinal pigmented epithelium in the involution of subretinal neovascularization. Invest Ophthalmol Vis Sci 1986; 27:1644-52.
81. Amin R, Pulkin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci 1994; 35:3178-88.
82. Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascularization membranes. Am J Ophthalmol 1996; 122:393-403.
83. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996; 37:855-68.
84. Yamada H, Yamada E, Kwak N, et al. Cell injury unmasks a latent proangiogenic phenotype in mice with increased expression of FGF2 in the retina. J Cell Physiol 2000; 185:135-42.
85. Nagai N, Oike Y, Izumi K, et al. Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. Arterioscler Thromb Vasc Biol 2006; 26:2252-9.
86. Seo M-S, Kwak N, Ozaki H, et al. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol 1999; 154:1743-53.
87. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is an important stimulator in a model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2000; 41:3158-64.
88. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351(27):2805-16.
89. Rosenfeld P, Brown DM, Heier J, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419-31.
90. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-44.
91. Yannuzzi LA, Wong DWK, Sforzolini BS, et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol 1999; 117: 1503-10.
92. Lafaut BA, Leys AM, Snyders B, Rasquin F, DeLaey JJ. Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthalmol 2000; 238:752-9.
93. Latfaut BA, Aisenbrey S, Broeck CV, Bartz-Schmidt KU. Clinicopathological correlation of deep retinal vascular anomalous complex in age-related macular degeneration. Br J Ophthalmol 2000; 84:1269-74.
94. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001; 21:416-34.
95. Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1982; 100:912-8.
96. Grey RHB, Bird AC, Chisholm IH. Senile disciform macular degeneration: features indicating suitability for photocoagulation. Br J Ophthalmol 1979; 63:85-9.
97. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesion of age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1990; 108:816-24.
98. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol 1994; 112:500-9.
99. Guyer DR, Fine SL, Maguire MG, Hawkins BS, Owens SL, Murphy RP. Subfoveal choroidal neovascular membranes in age-related macular degeneration. Visual prognosis in eyes with relatively good initial visual acuity. Arch Ophthalmol 1986; 104:702-5.
100. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol 1993; 115:786-91.
101. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol 1991; 109:1109-14.
102. Macular Photocoagulation Study Group. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol 1986; 104:503-12.
103. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Arch Ophthalmol 1990; 108:825-31.
104. Bressler SB, Bressler NM, Fine SL, et al. Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol 1982; 93:157-63.
105. Jalkh AE, Avila MP, Trempe CL, Schepens CL. Management of choroidal neovascularization within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol 1983; 95:818-25.
106. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991; 109:1220-31.
107. Macular Photocoagulation Study Group. Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration. Arch Ophthalmol 1996; 114:400-12.
108. Bressler NM, Frost LA, Bressler SB, Murphy RP, Fine SL. Natural course of poorly defined choroidal neovascularization associated with macular degeneration. Arch Ophthalmol 1988; 106:1537-42.
109. Soubrane G, Coscas G, Francais C, Koenig F. Occult subretinal new vessels in age-related macular degeneration. Natural history and early laser treatment. Ophthalmology 1990; 97:649-57.
110. Bressler NM, Maguire MG, Murphy PL, et al. Macular scatter (“grid”) laser treatment of poorly demarcated subfoveal choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol 1996; 114:1456-64.
111. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials—TAP Report 1. Arch Ophthalmol 1999; 117:1329-45.
112. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials—TAP Report 2. Arch Ophthalmol 2001; 119:198-207.
113. Verteporfin Roundtable 2000 Participants, Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, and Verteporfin in Photodynamic therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudynee) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002; 22:6-18.
114. Verteporfin In Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131:541-60.
115. VIO Study Group (in press).
116. Azab M, Boyer DS, Bressler NM, et al. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005; 123:448-57.
117. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 110:1517-25.
118. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration. Br J Ophthalmol 2004; 88:344-7.
119. Ergun E, Maar N, Ansari-Shahrezaei S, et al. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol 2006; 142:10-6.
120. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113:1508-21.
121. The VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular agerelated macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005; 25:815-27.
122. Regillo CD, Brown DM, Abraham H, Kaiser PK, Mieler WF. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2007 (in press).
123. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006; 124:1532-42.
124. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333:328-35.
125. Salesi N, Bossone G, Veltri E, et al. Clinical experience with bevacizumab in colorectal cancer. Anticancer Res 2005; 25:3619-23.
126. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112:1035-47.
127. Moshfeghi AA, Rosenfeld P J, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular agerelated macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006; 113:2002-11.
128. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36:331-5.
129. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26:495-511.
130. Godfrey DG, Waldron RG, Capone A, Jr. Transpupillary thermotherapy for small choroidal melanoma. Am J Ophthalmol 1999; 128:88-93.
131. Shields CL, Santos MC, Diniz W, et al. Thermotherapy for retinoblastoma. Arch of Ophthalmol 1999; 117:885-93.
132. Reichel E, Berrocal AM, Ip M, et al. Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology 1999; 106:1908-14.
133. Reichel E, Musch DC, Blodi BA, Mainster MA, TTT4CNV Study Group. Results from the TTT4CNV Clinical Trial. Invest Ophthalmol Vis Sci 2005; 46 (E-abstract 2311).
134. Archambeau JO, Mao XW, Yonemoto LT, et al. What is the role of radiation in the treatment of subfoveal membranes: review of radiobiologic, pathologic, and other considerations to initiate a multimodality discussion. Int J Radiat Oncol Biol Phys 1998; 40:1125-36.
135. Del Gowin RL, Lewis JW, Hoak JC, Mueller AL, Gibson DP. Radiosensitivity of human endothelial cells in culture. J Lab Clin Med 1974; 84:42-8.
136. Hosoi Y, Yamamoto M, Ono T, Sakamoto K. Prostacyclin production in cultured endothelial cells is highly sensitive to low doses of ionizing radiation. Int J Radiat Biol 1993; 63:631-8.
137. Sagerman RH, Chung CT, Alterti WE. Radiosensitivity of ocular and orbital structures. In: Alberti WE, Sagerman RH, eds. Radiotherapy of Intraocular and Orbital Tumors. Berlin: Springer, 1993:375-85.
138. Marcus DM, Peskin E, Maguire M, et al. The age-related macular degeneration radiotherapy trial (AMDRT): one year results from a pilot study. Am J Ophthalmol 2004; 138:818-28.
139. Submacular Surgery Trials Pilot Study Investigators. Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: I. ophthalmic outcomes. Am J Ophthalmol 2000; 130(4):387-407.
140. de Juan E, Jr., Loewenstein A, Bressler NM, Alexander J. Translocation of the retina for management of subfovealchoroidal neovascularization II: a preliminary report in humans. Am J Ophthalmol 1998; 125:635-46.
141. Fujii GY, Pieramici D, Humayun MS, et al. Complications associated with limited macular translocation. Am J Ophthalmol 2000; 130:751-62.
142. Lewis H, Kaiser PK, Lewis S, Estafanous M. Macular translocation for subfoveal choroidal neovascularization in age-related macular degeneration: a prospective study. Am J Ophthalmol 1999; 128:135-46.
143. Pertile G, Claes C. Macular translocation with 360 degree retinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularization. Am J Ophthalmol 2002; 134(4):560-5.
144. Mruthyunjaya P, Stinnett SS, Toth CA. Change in visual function after macular translocation with 360 retinectomy for neovascular age-related macular degeneration. Ophthalmology 2004; 111(9):1715-24.
145. Fujikado T, Asonuma S, Ohji M, et al. Reading ability after macular translocation surgery with 360-degree retinotomy. Am J Ophthalmol 2002; 134(6):849-56.
146. Toth CA, Lapolice DJ, Banks AD, Stinnett SS. Improvement in near visual function after macular translocation surgery with 360-degree peripheral retinectomy. Graefes Arch Clin Exp Ophthalmol 2004; 242(2):541-8.
147. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806-11.
148. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9:210-6.
149. Tolentino MJ, Brucker AJ, Fosnot J, et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 2004; 24:132-8.
150. Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006; 13:225-34.
151. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113:1522-32, 33.
152. Maier P, Unsoeld AS, Junker B, et al. Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graefes Arch Clin Exp Ophthalmol 2005; 243:593-6.
153. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000; 156:697-707.
154. Nambu H, Nambu R, Melia M, Campochiaro PA. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44:3650-5.
155. Moore KS, Wehrli S, Roder H, et al. Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci USA 1993; 90:1354-8.
156. Sills AK, Jr., Williams JI, Tyler BM, et al. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 1998; 58:2784-92.
157. Ciulla TA, Criswell MH, Danis RP, Williams JI, McLane MP, Holrovd KJ. Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina 2003; 23:808-14.
158. Garcia CA, Connolly B, Thomas E, et al. A phase 2 multi-dose pharmacokinetic study of MSI-1256F (squalamine lactate) for the treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci 2005; 46:E-Abstract 206.
159. Cashman SM, Bowman L, Christofferson J, Kumar-Singh R. Inhibition of choroidal neovascularization by adenovirus-mediated delivery of short hairpin RNAs targeting VEGF as a potential therapy for AMD. Invest Ophthalmol Vis Sci 2006; 47:3496-504.
160. West CM, Price P. Combretastatin A4 phosphate. Anticancer Drugs 2004; 15:179-87.
161. Vincent L, Kermani P, Young LM, et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 2005; 115: 2992-3006.
162. Mori K, Gelbach P, Ando A, McVey D, Wei L, Campochiaro PA. Regression of ocular neovascularization in response to increased expression of pigment epitheliumderived factor. Invest Ophthalmol Vis Sci 2002; 43:2428-34.
163. Rasmussen H, Chu KW, Campochiaro P, et al. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001; 2:2029-32.
164. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006; 17:177-9.
165. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 2006; 142:660-8.